Literature DB >> 11418877

Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.

H M Blumberg1, W R Jarvis, J M Soucie, J E Edwards, J E Patterson, M A Pfaller, M S Rangel-Frausto, M G Rinaldi, L Saiman, R T Wiblin, R P Wenzel.   

Abstract

To assess risk factors for development of candidal blood stream infections (CBSIs), a prospective cohort study was performed at 6 sites that involved all patients admitted to the surgical intensive care unit (SICU) for >48 h over a 2-year period. Among 4276 such patients, 42 CBSIs occurred (9.82 CBSIs per 1000 admissions). The overall incidence was 0.98 CBSIs per 1000 patient days and 1.42 per 1000 SICU days with a central venous catheter in place. In multivariate analysis, factors independently associated with increased risk of CBSI included prior surgery (relative risk [RR], 7.3), acute renal failure (RR, 4.2), receipt of parenteral nutrition (RR, 3.6), and, for patients who had undergone surgery, presence of a triple lumen catheter (RR, 5.4). Receipt of an antifungal agent was associated with decreased risk (RR, 0.3). Prospective clinical studies are needed to identify which antifungal agents are most protective and which high-risk patients will benefit from antifungal prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418877     DOI: 10.1086/321811

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  156 in total

1.  Emerging opportunistic fungal infections: where are we heading?

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2003-12       Impact factor: 1.798

2.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 3.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

Review 4.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

5.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

6.  Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.

Authors:  Maiken Cavling Arendrup; Kurt Fuursted; Bente Gahrn-Hansen; Irene Møller Jensen; Jenny Dahl Knudsen; Bettina Lundgren; Henrik C Schønheyder; Michael Tvede
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?

Authors:  Philippe Eggimann; Michel Wolff; Jorge Garbino
Journal:  Intensive Care Med       Date:  2005-09-30       Impact factor: 17.440

Review 8.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

9.  Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain.

Authors:  J Pemán; E Cantón; M Gobernado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

10.  Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.

Authors:  D L Horn; L Ostrosky-Zeichner; M I Morris; A J Ullmann; C Wu; D N Buell; L L Kovanda; O A Cornely
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-15       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.